1 / 49

Type 1 Diabetes: 2012 and Beyond

Type 1 Diabetes: 2012 and Beyond. Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas. Stem Cell Breakthrough .

gaura
Télécharger la présentation

Type 1 Diabetes: 2012 and Beyond

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Type 1 Diabetes:2012 and Beyond Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas

  2. Stem Cell Breakthrough • In a breakthrough that signifies a move toward a cure for type 1 diabetes, Australian researchers have identified stem cells in the pancreas that can be turned into insulin-producing cells.... • Identified and isolated stem cells from the adult pancreas, and then developed a way to coax them into insulin-producing cells that can secrete insulin in response to glucose. • 2012

  3. BCG • In the study, six insulin-dependent adults with type 1 diabetes received either two doses of BCG or two fake vaccinations. • In the three patients who received the vaccine: • "Bad" anti-insulin T cells began dying off. • New "good" regulatory T cells increased. • There were signs of new, albeit temporary, insulin production from pancreatic beta cells. • The vaccine was safe.

  4. Vitamin D Deficiency Linked to Type 1 Diabetes • (Nov, 2012) — A study led by researchers from the University of California, San Diego School of Medicine has found a correlation between vitamin D3 serum levels and subsequent incidence of Type 1 diabetes. • The six-year study of blood levels of nearly 2,000 individuals suggests a preventive role for vitamin D3 in this disease.

  5. Quest to prolong the action of insulin • 1930’s-- development of protamine zinc insulin • Lente, NPH, and ultralente were developed as suspensions to prolong action by delaying absorption • Glargine and detemir were developed to prolong subcutaneous absorption by altering amino acid structure (glargine) or adding fatty acylated side chains (detemir)

  6. “Ideal” Basal Insulin • The “ideal” longer acting insulin may be expected to • Reduced variability • Lower risk of hypoglycemia, • Reduce the need for twice-daily injections • Provide minimal peak activity • Restore physiologic distribution of the 2-fold portal to systemic insulin levels • Subcutaneous systemic absorption results in similar portal and systemic levels • With current insulins, reduced hepatic insulin action must be balanced with excess peripheral insulin action to maintain glucose homeostasis.

  7. Basal Insulins in Development

  8. Insulin Degludec-Novel Basal Insulin • Forms a depot of soluble multi-hexamers at the injection site • Half-life of ~25 hours and a consistent glucose-lowering effect of >42 hours

  9. Insulin Degludec

  10. Degludec: Basal-Bolus Type 1

  11. LY2605541

  12. Pharmacodynamic Profiles of LY2605541 Heise, et al, Poster ADA 2012

  13. Better Glycemic Control and Weight Loss with the Novel Long-Acting Basal InsulinLY2605541 Compared with Insulin Glargine in Patients with Type 1 DiabetesJulio Rosenstock, Richard M. Bergenstal, Thomas Blevins, Linda A. Morrow, Melvin J. Prince, YongmingQu,VikramP. Sinha, Daniel C. Howey, Scott J.Jacober ADA, 2012, abstracts/poster session

  14. Change in A1c ADA, 2012, abstracts/poster session

  15. Change in Weight ADA, 2012, abstracts/poster session

  16. Prandial (Pre-meal) Insulin

  17. Injected Prandial InsulinRapid Actingor Very Rapid Acting (Warp Speed?)

  18. Do We Need Ultrafast Insulin? • Current analog insulin is slower than the physiologic prandial insulin response of healthy individuals • Typical time to peak insulin concentration is 45-60 minutes for healthy subjects vs. 60-100 minutes for analog prandial insulin • Tail of insulin action is longer than physiologic response and leads to 3- 6 hour post meal hypoglycemia (including nocturnal hypoglycemia) • Prandial control is elusive for even “well-controlled” patients • Majority of patients fail to achieve Post-Prandial Glucose (PPG) goals • Current analog insulin requires approximately 15-20 minutes meal delay

  19. Hyaluronin and Hyaluronidase • Hyaluronan (hyaluronic acid) Structure/Function • Until the late 1970s, hyaluronan was described as a "goo" molecule, a ubiquitous carbohydratepolymer that is part of the extracellular matrix • Large (Mega Dalton), repeating sugar polymer found in interstitial tissues • Forms barrier to bulk fluid flow in interstitial space • Human body turns over more than 5 grams/day (1/3rd of total body pool) • Hyaluronidase Mechanism of Action • Catalyzes the rapid depolymerization of hyaluronan • Locally-acting, transient removal of the hyaluronan barrier to enhance the dispersion of coinjected drugs • Rapid dispersion enhances insulin dissociation kinetics and accelerated absorption into the systemic circulation SC administered drug depot rHuPH20 disperses SC administered drugs

  20. Pharmacokinetic Results • The three marketed rapid acting analog insulins have similar time exposure profiles Morrow et al. ADA oral presentation 2010

  21. Pharmacokinetic Results • Faster In (Primary Endpoint): • With rHuPH20 insulin exposure in the 1st hour was 191%, 229%, and 246% of control for glulisine, lispro and aspart, respectively(all P< 0.0001) • Faster Out: • Insulin exposure after 2 hours decreased by 43%, 54%, and 57% for PH20 coinjection with glulisine, lispro and aspart, respectively (all P< 0.0001) Morrow et al. ADA oral presentation 2010

  22. Human Hyaluronidase + Rapid Analog Insulin (RAI) Improves Postprandial Glycemic Control in Type 1 Diabetes Compared to Insulin Lispro Alone IRL B. HIRSCH, JAY S SKYLER, SATISH GARG, THOMAS BLEVINS, DANIEL E VAUGHN, DOUGLAS B MUCHMORE University of Washington, Seattle, WA; University of Miami, Miami, FL; University of Colorado Denver, Aurora, CO; Texas Diabetes and Endocrinology, Austin, TX; Halozyme Therapeutics, San Diego, CA Hirsch et al, ADA 2012 Poster

  23. T1DM: Improved Prandial Control with Analog-PH20 Demonstrated Throughout Study • Overall mean PPG change (90 minutes) from pre-meal baseline, routine SMBG monitoring throughout each treatment phase. Confidential

  24. Artificial Pancreas

  25. Closed loop “automatic” systems (pump-sensor)

  26. Is Hypoglycemia a Challenge? • Do some of your adults or children with diabetes suffer from: • Hypoglycaemia Unawareness? • Nocturnal Hypoglycaemia? • Or a fear of Hypoglycaemia?

  27. Medtronic MiniMed Guardian® REAL-Time Continuous Glucose Monitoring System How to Address this Challenge? • Current Therapy Options • CSII vs MDI • Continuous Glucose Monitoring (CGM) • Advanced Therapy Options • Sensor-augmented Pumps • Automatic Insulin Shut-off Mechanism

  28. Diabetes Technology Explosion

  29. 2 3 1 CSII Reduces Incidents of Severe Hypoglycaemia1/4 Severe Hypoglycaemic Episodes: CSII vs MDI 1 Rudolph JW, Hirsch IB. Endocrine Pract 2002: 8; 401 – 405 2 Bode, BW et al., Diabetes Care 1996, 19:325-7. 3 Boland, EA et al., Diabetes Care 1999, 22:1779 - 84. 4 Pickup JC & Sutton, AJ. Diabet Med 2008;25:765-774

  30. Period 1 Period 2 p=0.004 p=0.03 33.6 Minutes per event Alerts off Alerts off Alerts off Alerts on CGM Alerts Reduce Duration of Hypoglycaemic Excursions1 • 71 Type 1 patients wore sensors over a 12-day period • Multi-Center RCT where patients were randomised to: • Alert Group • Alerts On 50% • Alerts Off 50% • Control Group • Alerts Off CGM alerts improve glycemic control 1. Bode et al. 2004 Diab.Tech & Therapeutics 6(2): 105-113.

  31. Sensor Report

  32. The Road to Closing the Loop

  33. The Road to Closing the Loop • Low Glucose Suspend • Predictive low glucose • High glucose bolus • Predictive high glucose bolus • True closed loop

  34. How Does Low Glucose Suspend Work? • User settable: On/Off • Range: Trigger at <50 mg/dl • Fictional illustration of Low Glucose Suspend function in use • Suspends insulin infusion for a 2-hour period • All other sensor functions and alerts remain operational during insulin suspension

  35. Low Glucose Suspend is the first component of the closed loop • Reduces the severity of hypoglycemia • Complements the CGM alerts • Provides an additional safety measure for an unresponsive patient

  36. LGS – CareLinkTMTherapy Management Software Tracing

  37. Introducing the MiniMed Paradigm® Veo™ SystemA new era in diabetes management • Greater protection from severe hypoglycaemia • Automatic insulin shut-off mechanism – Low Glucose Suspend (LGS) • Greater protection from glycaemic excursions • CGM-ready insulin pump • Combined CSII and CGM offer clinical benefits1 • CGM alerts • Give early warnings of glycaemic excursions • Reduce the duration of hypoglycaemic excursions2 • Improved sensor sensitivity in the hypoglycaemic range • Closing the loop • First device to offer sensor-driven adjustments to insulin delivery 1. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765-774 2. Bode B., et al. Diabetes Technology and Therapeutics. Volume 6, Number 2, 2004

  38. Veo system: patient view

  39. Examples of Successful Inductions

  40. Effect of LGS on hypoglycemia • Reduction in severe hypoglycemic blood glucose levels is observed with LGS Fig. Comparison of low sensor BG when LGS is OFF vs. ON Percent time SG <= 50 Percent time SG <= 80 **”Characterization of the Low Glucose Suspend Feature of the Medtronic Paradigm Veo Insulin Pump and Events Preceding its Activation” . To be presented by Dr. Fran Kaufman at the ADA conference 2011

  41. Fictional illustration of alerts in use

  42. Studies Done at Here in Austin at Texas Diabetes and Endocrinology • Basal Insulin • Degludec • Basal insulin lispro (BIL) • Rapid, pre-meal insulin (warp speed) • Halozyme • Biodel • Insulin pump-LGS (low glucose suspend)

  43. Studies- ongoing or coming up for Type 1’s • Sanofi U300- Lantus pen • Concentrated insulin, lower volume • 3 units for every 1 traditional unit • Halozyme- Insulin pump with very rapid acting insulin • Eli Lily BIL basal insulin flex dosing • Given in the am or pm-flat profile • Liraglutide in Type 1’s • The agent that lowers glucose and glucagon with weight loss in Type 2 diabetes • Novo Degludec • Long acting, basal insulin with flat profile.

  44. “Smart Insulin” • “Smart Insulin” works via competitive binding • insulin (orange lines), attached to a sugar group (orange hexagons), binds with a sugar-binding molecule (blue circle) in solution. • When glucose (blue hexagons) in the body is high, it competes with insulin to bind to the sugar-binding molecules, displacing insulin and releasing it into the bloodstream as needed

  45. Q and A

More Related